Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1513009

This article is part of the Research Topic Repurposing Cancer Immunotherapies for Use in Autoimmunity and Transplantation View all 7 articles

CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs

Provisionally accepted
Matteo Doglio Matteo Doglio 1Jyoti Rana Jyoti Rana 2Adriana Stucchi Adriana Stucchi 3Maite Münoz Melero Maite Münoz Melero 2Alessia Ugolini Alessia Ugolini 1Tatiana Jofra Tatiana Jofra 3Sandeep Kumar Sandeep Kumar 1Paolo Monti Paolo Monti 3Elisa Martini Elisa Martini 1Senthilkumar Thirumurugan Senthilkumar Thirumurugan 2Moanaro Biswas Moanaro Biswas 2*Chiara Bonini Chiara Bonini 1*Georgia Fousteri Georgia Fousteri 3*
  • 1 Experimental Hematology Unit, Division of Immunology,Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy
  • 2 School of Medicine, Indiana University Bloomington, Indianapolis, Indiana, United States
  • 3 Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute (IRCCS), Milan, Lombardy, Italy

The final, formatted version of the article will be published soon.

    Secondary and tertiary lymphoid structures are a critical target of suppression in many autoimmune disorders, protein replacement therapies, and in transplantation. Although antigen-specific regulatory T cells (Tregs), such as chimeric antigen receptor (CAR) Tregs, generally persist longer and localize to target tissues more effectively than polyclonal Tregs in animal models, their numbers still progressively decline over time. A potential approach to maximize Treg activity in vivo is the expression of chemokine receptors such as CXCR5, which would enable localization of a greater number of engineered cells at sites of antigen presentation. Indeed, CXCR5 expression on follicular T helper cells and follicular Tregs enables migration toward lymph nodes, B cell zones, and tertiary lymphoid structures that appear in chronically inflamed non-lymphoid tissues. In this study, we generated human and murine CXCR5 co-expressing engineered receptor Tregs and tested them in preclinical mouse models of allo-immunity and hemophilia A, respectively. In vitro, anti-HLA-A2 CXCR5 + CAR-Tregs showed enhanced migratory and antigen-specific suppressive capacities compared to untransduced Tregs. When injected into an NSG mouse model of HLA-A2 + pancreatic islet transplantation, anti-HLA-A2 CXCR5 + CAR-Tregs maintained a good safety profile allowing for long-term graft survival in contrast to anti-HLA-A2 CXCR5 + conventional CAR-T (Tconv) cells that eliminated the graft. Additionally, we engineered a murine CXCR5 co-expressing clotting factor VIII (FVIII) specific T cell receptor fusion construct epsilon (FVIII TRuCe CXCR5 Treg), which improved in vivo Treg persistence and suppressive capacity in a model of FVIII replacement therapy for hemophilia A. Collectively, our findings indicate that CXCR5 co-expression is safe and enhances in vivo localization and persistence in target tissues. This strategy can potentially promote targeted tolerance without the risk of off-target effects in multiple disease models.

    Keywords: Regulatory T cells (Tregs), C-X-C chemokine receptor type 5 (CXCR5), Type 1 diabetes (T1D), Pancreatic islet transplantation, Hemophilia, chimeric antigen receptor (CAR), TCR fusion construct epsilon (TRuCe)

    Received: 17 Oct 2024; Accepted: 25 Mar 2025.

    Copyright: © 2025 Doglio, Rana, Stucchi, Melero, Ugolini, Jofra, Kumar, Monti, Martini, Thirumurugan, Biswas, Bonini and Fousteri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Moanaro Biswas, School of Medicine, Indiana University Bloomington, Indianapolis, Indiana, United States
    Chiara Bonini, Experimental Hematology Unit, Division of Immunology,Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 20132, Lombardy, Italy
    Georgia Fousteri, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute (IRCCS), Milan, 20132, Lombardy, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more